Cargando…

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile

BACKGROUND: Use of vancomycin to treat Clostridioides difficile infection (CDI) has increased following recent IDSA/SHEA treatment guideline updates, applying a selection pressure for resistance development. We previously demonstrated acquired mutations in VanSR two-component system led to constitut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eubank, Taryn A, Dureja, Chetna, Hurdle, Julian G, Garey, Kevin W, Gonzales-Luna, Anne J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752053/ http://dx.doi.org/10.1093/ofid/ofac492.458

Ejemplares similares

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

674. Host and Pathogen Risk Factors for Fulminant Clostridioides difficile Infection
por: Chua, Hubert C, et al.
Publicado: (2023)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile
por: Olaitan, Abiola O., et al.
Publicado: (2023)

840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

18. Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings
por: Jo, Jinhee, et al.
Publicado: (2021)

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
por: Dureja, Chetna, et al.
Publicado: (2023)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

2402. Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

802. Proton Pump Inhibitors Increase Clostridioides difficile Disease Severity Controlling for Infecting Strains
por: Fallatah, Saad, et al.
Publicado: (2020)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

795. Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Guideline on the Classification of Clostridioides difficile Infection Severity
por: Carlson, Travis J, et al.
Publicado: (2020)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes
por: Carlson, Travis J, et al.
Publicado: (2019)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

Complete Genome Sequence of Clostridioides difficile Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing
por: Spinler, Jennifer K., et al.
Publicado: (2019)

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
por: McPherson, Jacob, et al.
Publicado: (2022)

Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection
por: Alonso, Carolyn D, et al.
Publicado: (2021)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection
por: Ke, Shanlin, et al.
Publicado: (2021)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection
por: Dotson, Kierra M, et al.
Publicado: (2019)

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
por: Hengel, Richard L., et al.
Publicado: (2022)

Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
por: Carlson, Travis J, et al.
Publicado: (2021)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

Epidemiology of Clostridioides difficile in South Africa
por: de Jager, Pieter, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

2378. Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients
por: Carlson, Travis J, et al.
Publicado: (2019)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k2kgkhlgf09eq0aeksr50ke9mq